Opus Genetics (NASDAQ:IRD) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.14) by 435.71 percent. This is a 212.5 percent decrease over losses of $(0.24) per share from the same period last year. The company reported quarterly sales of $2.157 million which missed the analyst consensus estimate of $2.931 million by 26.42 percent. This is a 50.64 percent decrease over sales of $4.370 million the same period last year.